Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23560891 | 0.89 | MAPT (0.46) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL24091782 | 0.88 | GPR119 (0.53) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL23784871 | 0.87 | MAPT (0.57) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL24851896 | 0.86 | GPR119 (0.50) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL7581350 | 0.86 | MAPT (0.53) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1497394 | 0.86 | SMN1; SMN2 (0.49) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL25763139 | 0.85 | MAPT (0.43) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL21667796 | 0.84 | MAPT (0.54) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL26604111 | 0.84 | MAPT (0.54) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1432796 | 0.84 | POLB (0.53) | MAPTALDH1A1LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673441-A1 | LZK INHIBITORS | Ureka Bioscienes, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182552-A1 | LZK INHIBITORS | UEREKA BIOSCIENCES, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-107922427-B | Antiviral compounds | 詹森生物制药有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-2616441-B1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| EP-3262048-A1 | ANTIVIRAL COMPOUNDS | Alios Biopharma, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9611222-B2 | Pyridine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2017-04-04 | — | — | US | disclosed |
| WO-2016138158-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016138158-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-09-17 | — | — | US | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056832-B2 | Pyridine compounds and the users thereof | PURDUE PHARMA L.P. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012035421-A2 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259293-A1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, CACNA1A, KCNA1 | MAPT 3114/4885ALDH1A1 172/4885LMNA 1483/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | MAPT 4665/4885ALDH1A1 4011/4885LMNA 2978/4885 |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | MAPT 4665/4885ALDH1A1 4011/4885LMNA 2978/4885 |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | TRPV1, CACNA1A, KCNA1 | MAPT 3114/4885ALDH1A1 172/4885LMNA 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.